Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CHPA pushes for DXM bill

This article was originally published in The Tan Sheet

Executive Summary

The Consumer Healthcare Products Association "already has begun an initiative to seek reintroduction" of the Dextromethorphan Distribution Act of 2006 in the next session of Congress since the Senate did not address the legislation before Congress adjourned Dec. 9. The bill, which passed the House by voice vote Dec. 6, would allow FDA to limit the distribution of bulk ingredient DXM to people or entities registered with the agency, and would make it more difficult for teens to abuse the drug (1"The Tan Sheet" Dec. 11, 2006, p. 11). "We are committed to educating and empowering parents to take responsibility and action by informing their children of the dangers of abusing both Rx and OTC medicines," CHPA President Linda Suydam states in the association's executive newsletter Dec. 15...

You may also be interested in...

Dextromethorphan Bulk-Sale Limit Clears House, But Stalls In Senate

House leadership made a lame duck priority of legislation to restrict sales and distribution of bulk forms of dextromethorphan (DXM), but HR 5280 did not get the same treatment in the Senate

US FDA Commissioner Hahn’s Star Turn: Baptism By Fire Turns Perilous

FDA Commissioner Stephen Hahn was added to the White House's pandemic task force as the outbreak grew, but he remained in a background role. That all changed the morning of 18 March, when President Trump tweeted: “I will be having a news conference today to discuss very important news from the FDA concerning the Chinese Virus!” A day later, Hahn was standing with Trump at the podium for the now-daily press briefings on Covid-19.

Biohaven’s Nurtec May Be First Migraine Drug For Acute Treatment And Prevention

Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts